
    
      According to sample size calculation 30 newly diagnosed hematologic malignant patients and 30
      healthy individuals will be included. Before treatment submaximal exercise capacity, physical
      activity, quality of life, pulmonary functions, respiratory and peripheral muscle strength,
      respiratory muscle endurance, dyspnea and fatigue perception, anxiety and depression will be
      evaluated. Primary outcome measurements are exercise capacity, physical activity, quality of
      life, secondary outcomes are respiratory and peripheral muscle strength, respiratory muscle
      endurance, pulmonary functions, dyspnea and fatigue perception, anxiety and depression.
    
  